According to recent review released by the Food and Drug Administration patients who suffer from heartburn are not at increased risk for heart problems as a result of taking Prilosec or Nexium. The FDA and its Canadian counterpart began reviewing the drugs, used by tens of millions of people, in May.
The drug’s manufacturer, AstraZeneca PLC, provided them with an early analysis of two small studies that suggested the possibility of a risk.
The agency said its review of that study as well as 14 others indicated no increased risk for patients.
“FDA recommends that health care providers continue to prescribe, and patients continue to use these products as prescribed,” the agency said.
Well it is a great news for us – heartburn sufferers. We can take our Protonixes, Prilosecs and Nexiums without worrying about consequences too much .
I hope they will do more research regarding all other concerns related to long term PPI treatment like malnutrition, potential lung diseases, etc. For example:
Journal of Clinical Gastroenterology. 30(1):29-33, January 2000.
Howden, Colin W.
Reduced serum vitamin B12 (cobalamin) levels have been documented occasionally during long-term treatment with a proton pump inhibitor (PPI) in selected groups of patients. This has largely been confined to patients being treated for Zollinger-Ellison syndrome who have sustained drug-induced achlorhydria, which does not ordinarily occur during treatment with a PPI. An appreciation of normal cobalamin metabolism and the pharmacological action of the PPIs adequately explain the mechanism for this reduction. PPIs do not promote the development of pernicious anemia.